Page 1,050«..1020..1,0491,0501,0511,052..1,0601,070..»

Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted: April 26, 2020 at 8:44 am

Mesoblast limited (MESO) is near the top in its industry group according to InvestorsObserver. MESO gets an overall rating of 82. That means it scores higher than 82 percent of stocks. Mesoblast limited gets a 95 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mesoblast limited (MESO) stock is trading at $16.61 as of 10:30 AM on Friday, Apr 24, an increase of $10.16, or 157.52% from the previous closing price of $6.45. The stock has traded between $14.33 and $20.57 so far today. Volume today is above average. So far 12,327,011 shares have traded compared to average volume of 428,508 shares.

To screen for more stocks like MESO click here.

Originally posted here:
Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Mesoblast limited (MESO) Stock Fall in the Biotechnology Field? – InvestorsObserver

Insights on the Worldwide Biotechnology Reagents Industry to 2024 – Drivers, Challenges and Trends – ResearchAndMarkets.com – Business Wire

Posted: April 26, 2020 at 8:44 am

DUBLIN--(BUSINESS WIRE)--The "Global Biotechnology Reagents Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The biotechnology reagents market is poised to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period. The report on the biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of high-throughput and novel technologies and high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, the presence of high-throughput and novel technologies is anticipated to boost the growth of the market as well.

This study identifies the increasing R&D investments by federal agencies and biotechnology firms as one of the prime reasons driving the biotechnology reagents market growth during the next few years.

Companies Mentioned

Key Topics Covered:

1. Executive Summary

2. Market Landscape

3. Market Sizing

4. Five Forces Analysis

5. Market Segmentation by Technology

6. Customer landscape

7. Geographic Landscape

8. Drivers, Challenges, and Trends

9. Vendor Landscape

10. Vendor Analysis

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jdmnpl.

Visit link:
Insights on the Worldwide Biotechnology Reagents Industry to 2024 - Drivers, Challenges and Trends - ResearchAndMarkets.com - Business Wire

Posted in Biotechnology | Comments Off on Insights on the Worldwide Biotechnology Reagents Industry to 2024 – Drivers, Challenges and Trends – ResearchAndMarkets.com – Business Wire

Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

Posted: April 26, 2020 at 8:44 am

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 3.56% from its latest closing price when compared to the 1-year high value of $75.00 and move down -140.77%, while VIR stocks collected +6.21% of gains with the last five trading sessions. Press Release reported on 04/15/20 that VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

VIR stocks went up by 6.21% for the week, with the monthly drop of -4.89% and a quarterly performance of 83.45%. The simple moving average for the period of the last 20 days is 0.29% for VIR stocks with the simple moving average of 44.30% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -58.47% of loss for the given period.

The stock volatility was left at 11.09%, however, within the period of a single month, the volatility rate increased by 7.37%, while the shares surge at the distance of +1.30% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +70.78% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +6.21%. In addition, Vir Biotechnology, Inc. saw 147.71% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Original post:
Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? - The News Heater

Posted in Biotechnology | Comments Off on Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? – InvestorsObserver

Posted: April 26, 2020 at 8:44 am

The 75 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 87 percent of stocks in the Biotechnology industry, CARAs 75 overall rating means the stock scores better than 75 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cara Therapeutics Inc (CARA) stock is trading at $15.81 as of 11:14 AM on Wednesday, Apr 22, a rise of $0.39, or 2.53% from the previous closing price of $15.42. The stock has traded between $15.29 and $16.44 so far today. Volume today is below average. So far 328,715 shares have traded compared to average volume of 541,813 shares.

To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.

Read more here:
Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? - InvestorsObserver

Posted in Biotechnology | Comments Off on Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? – InvestorsObserver

Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months – The InvestChronicle

Posted: April 26, 2020 at 8:44 am

Lets start up with the current stock price of Vir Biotechnology, Inc. (VIR), which is $31.15 to be very precise. The Stock rose vividly during the last session to $31.4 after opening rate of $29.55 while the lowest price it went was recorded $29.55 before closing at $30.08.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -58.47% during the 52-week period from high price, and 167.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.56 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 147.71%, having the revenues showcasing 83.45% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.41B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 24.32, with a change in the price was noted +19.25. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +161.76% for the period of last 100 days, recording 780,574 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 25.56%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.58%. In the last 20 days, the companys Stochastic %K was 27.22% and its Stochastic %D was recorded 25.85%.

Bearing in mind the latest performance of Vir Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 147.71%. The shares increased approximately by 1.57% in the 7-day charts and went up by 6.21% in the period of the last 30 days. Common stock shares were driven by 83.45% during last recorded quarter.

The rest is here:
Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months - The InvestChronicle

Posted in Biotechnology | Comments Off on Vir Biotechnology, Inc. (VIR) is on the roll with an average volume of 1.13M in the recent 3 months – The InvestChronicle

Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted: April 26, 2020 at 8:44 am

Intercept Pharmaceuticals Inc (ICPT) is near the top in its industry group according to InvestorsObserver. ICPT gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Intercept Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Intercept Pharmaceuticals Inc (ICPT) stock is trading at $81.86 as of 10:41 AM on Tuesday, Apr 21, a loss of -$0.75, or -0.91% from the previous closing price of $82.61. The stock has traded between $80.53 and $83.30 so far today. Volume today is less active than usual. So far 80,863 shares have traded compared to average volume of 667,682 shares.

To see InvestorsObserver's Sentiment Score for Intercept Pharmaceuticals Inc click here.

See original here:
Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field? – InvestorsObserver

Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 – Cole of Duty

Posted: April 26, 2020 at 8:44 am

The Chromatography in Pharmaceuticals and Biotechnology Market report shows a brilliant presentation of regional growth, competition and provides accurate statistics with price and gross margin and other essential factors to grow in the Chromatography in Pharmaceuticals and Biotechnology market. The Chromatography in Pharmaceuticals and Biotechnology market report digs deep into critical aspects of key subjects which help market players to make appropriate changes in their approach and help you craft better strategies. The report is made with a combination of detailed information relying upon the important data researched by our analysts.

Chromatography is a continuously evolving technique, and its success is dependent on the innovations in technology. Therefore, this report discusses the emerging trends in chromatography technology, particularly the instruments and the reagents. It also features the new developments and new product launches in the global market.

The report provides relevant patent analyses and comprehensive profiles of market players in the industry. The Industry Structure chapter focuses on the important chromatography instruments and reagent manufacturers and suppliers, their market shares and product offerings. The chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

BCCs new report on chromatography elaborates on the strengths, weaknesses, threats and opportunities of the global chromatography market. Any regulatory changes or new initiatives are also highlighted.

Get Sample Copy of this Report @https://www.reportsintellect.com/sample-request/698611

Chromatography in Pharmaceuticals and Biotechnology Market report provides competitive analysis which helps clients to become aware of the unique characteristics of crucial factors impacting the market competition and hence changing their growth potential by manifold. Chromatography in Pharmaceuticals and Biotechnology market report provides accurate market data, market dynamics, and key segments.

Get Discounted Report @https://www.reportsintellect.com/discount-request/698611

Table of Contents:-

Highlights of the worldwide Chromatography in Pharmaceuticals and Biotechnology Market Report:

About us:

Reports Intellect provides research reports for everything related to market research and market intelligence. We understand the importance of the market with its needs in todays competitive world.

Our team works to obtain the most authentic research reports, accompanied by perfect data figures which guarantee exceptional results for you and your company every time.

Our team is there to help you in the best possible way, whether it is the latest report from the researchers or a personalized requirement, do not hesitate to contact us.

Contact us:

[emailprotected]

PH + 1-706-996-2927

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Read more from the original source:
Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 - Cole of Duty

Posted in Biotechnology | Comments Off on Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 – Cole of Duty

Boiling and ready to burst as Puma Biotechnology, Inc. (PBYI) last month performance was 15.35% – The InvestChronicle

Posted: April 26, 2020 at 8:44 am

For the readers interested in the stock health of Puma Biotechnology, Inc. (PBYI). It is currently valued at $10.67. When the transactions were called off in the previous session, Stock hit the highs of $10.8, after setting-off with the price of $10.59. Companys stock value dipped to $10.12 during the trading on the day. When the trading was stopped its value was $10.47.

Puma Biotechnology, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $35.22 on 04/25/19, with the lowest value was $5.50 for the same time period, recorded on 03/17/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Puma Biotechnology, Inc. shares are logging -69.70% during the 52-week period from high price, and 94.00% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $5.50 and $35.22.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 660400 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Puma Biotechnology, Inc. (PBYI) recorded performance in the market was 21.94%, having the revenues showcasing 31.73% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 417.41M, as it employees total of 269 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.36, with a change in the price was noted +1.18. In a similar fashion, Puma Biotechnology, Inc. posted a movement of +12.43% for the period of last 100 days, recording 1,853,577 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for PBYI is recording 5.43 at the time of this writing. In addition, long term Debt to Equity ratio is set at 5.43.

Raw Stochastic average of Puma Biotechnology, Inc. in the period of last 50 days is set at 54.71%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 84.84%. In the last 20 days, the companys Stochastic %K was 80.66% and its Stochastic %D was recorded 81.51%.

If we look into the earlier routines of Puma Biotechnology, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 21.94%. Additionally, trading for the stock in the period of the last six months notably improved by 47.78%, alongside a downfall of -68.25% for the period of the last 12 months. The shares increased approximately by 24.61% in the 7-day charts and went down by 10.57% in the period of the last 30 days. Common stock shares were driven by 31.73% during last recorded quarter.

Read the original:
Boiling and ready to burst as Puma Biotechnology, Inc. (PBYI) last month performance was 15.35% - The InvestChronicle

Posted in Biotechnology | Comments Off on Boiling and ready to burst as Puma Biotechnology, Inc. (PBYI) last month performance was 15.35% – The InvestChronicle

All your questions about how to wear a face mask — answered – Action News Now

Posted: April 26, 2020 at 8:41 am

Face masks can be unexpectedly complicated, especially for those who are new to wearing them.

Navigating which ones you should buy and understanding who they protect, figuring out if you can reuse them and how to get your little ones to wear them are daunting tasks.

Social distancing is still our best bet to prevent further spread of the coronavirus. But since April 3, Americans have been encouraged by the US Centers for Disease Control and Prevention to wear "cloth coverings" in places where distancing guidelines are hard to maintain.

But is your bandana really helping you? Should only people who know they're infected wear masks? And what if your kids throw a tantrum when you ask them to put one on?

We answer every question readers have been asking about face masks.

On April 3, the CDC shifted its guidelines to recommend that we should wear "cloth coverings" in public places where other social distancing measures are difficult to maintain, such as grocery stores and pharmacies.

The updated guidance was in light of new evidence of the high percentage of people spreading the virus asymptomatically. This means the virus can easily spread between people interacting in close proximity by coughing, sneezing or even talking -- even if those people aren't exhibiting symptoms.

Some states require citizens to wear masks in public spaces -- such as Connecticut, Hawaii, Maryland, New Jersey, New York, Pennsylvania and Rhode Island, as of April 20. Some countries, including Germany, Turkey and Jamaica, have required to some degree that people wear masks.

The benefit of wearing masks in public isn't to protect you from getting sick. It's to protect others from exposure if you are sick or if you're an asymptomatic carrier. But if we all wear masks, we could help each other, said Dr. Joseph Vinetz, a professor in the infectious disease section at Yale School of Medicine.

"The idea about the face mask is to prevent the virus from coming out of somebody's mouth and nose, mostly out of their mouth," Vinetz said. "They prevent somebody, when they talk or sometimes when they sneeze or cough, from expelling virus and leading to infection in other people."

Wearing a mask doesn't totally prevent you from getting infected, Vinetz added. The virus can live on surfaces for hours, and in trace amounts up to three days, and it's easy to touch your face when you're not wearing a mask.

Even if you wear a mask, maintaining 6-feet social distancing is still important to slowing the spread of the virus. The CDC considers face masks an additional, voluntary public health measure -- but remember to refer to your home state's guidance as well.

Though the CDC recommends we wear masks, we shouldn't buy surgical masks or N95 respirator masks. Those types are desperately needed by health care workers and first responders who are in constant proximity with coronavirus patients every day, and supplies in some areas are dwindling.

You can, however, easily make your own cloth mask from old clothes or other common materials and household items. And you don't even have to sew. You can make one using a bandana and coffee filter. US Surgeon General Jerome Adams showed us how to make face masks with a T-shirt and rubber bands in this CDC video.

"Ultimately, it's about having some form of barrier with multiple layers," said CNN Chief Medical Correspondent Dr. Sanjay Gupta in a CNN video on why masks in addition to physical distancing are important.

Masks made with a combination of cotton with natural silk or chiffon may also effectively filter out aerosol particles, according to a new study published Friday in the American Chemical Society Nano journal. Our respiratory droplets form in a range of sizes, but the tiny ones, called aerosol particles, can slip through the gaps between certain cloth fibers.

You could substitute the chiffon with natural silk or flannel, or use a cotton quilt with cotton-polyester insulation, to achieve similar results, the study said.

There are also disposable cloth masks you can buy in a store or online. They're not made for surgery or hospitals, but they are effective for your needs and widely used.

"When we talk about face coverings, there are the surgical masks I wear in the hospital to protect patients from my own germs and avoid any splashes," said Gupta, who works as a neurosurgeon.

N95 respirators are masks that must be fitted to the faces of health care workers to protect them during certain procedures, Gupta added.

"It's the only one of these masks that prevents most very small particles from getting in, when used properly," he continued. "We need to keep those masks in their hands."

Medical-grade masks are more effective, but that "doesn't mean we should dismiss the benefit of cloth masks," Gupta said.

Because of how far our respiratory droplets travel when we talk, cough or sneeze, face masks can still help to contain the range of those droplets.

The researchers in the Nano study used sodium chloride to replicate respiratory particles ranging in size, and blew with a fan the particles across material samples at a rate similar to a person's resting breath. They measured the number and size of particles in the air before and after they passed through the fabric.

One layer of a tightly woven cotton sheet combined with two layers of polyester-spandex chiffon filtered out the most air particles, between 80% to 99%. According to the study, its effectiveness was close to an N95 mask.

Tightly woven fabrics such as cotton can be a mechanical barrier to particles, while fabrics with a static charge, such as natural silk or chiffon, act as a electrostatic barrier, the study said.

However, a very small gap reduced the efficacy of the mask by at least 50%, emphasizing the importance of a properly fitted mask, the study said.

Homemade masks can be reused because they're washable, Vinetz said.

You should launder the masks before and after each use to clean off any germs you may have picked up in public. Hand-wash the masks or put them in a mesh wash bag in the washing machine so they don't come apart, and use a high-heat setting.

If you already have a disposable surgical or medical-grade mask, those can be reused, too. To disinfect it, leave it in a clean, safe place in your house for a couple days, Vinetz suggested. After that, it should no longer be infectious.

If you're thinking you might be able to nuke your mask to kill germs, that's "not a great idea," Vinetz said.

"We have no evidence about that," he said. "If there's a metal piece in an N95 or surgical mask and even staples, you can't microwave them. It'll blow up. If you have a homemade or cloth mask or what's called a face covering, you just wash it. Microwaving it is not going to work."

For those who wear glasses, wearing a mask means figuring out how to avoid our humid breath blocking us from seeing across the grocery store. Or from seeing anything, really.

"To avoid fogging up your glasses -- I have the problem myself -- short of getting Lasik surgery, you have to fold the mask around your nose so that the air coming out of your mouth or nose doesn't rise to your glasses," Vinetz said. (He's not recommending anyone get elective surgery right now.)

If your child refuses to wear a mask, takes it off and throws it down, chews on it or otherwise, his actions could defeat the point of wearing a mask and raise the risk of infection, said Christopher Willard, a psychiatry lecturer at Harvard Medical School and author of "The Breathing Book," a breathing practice book for kids.

Kids may be apprehensive about wearing a face mask because they're more sensitive to new things than adults are, Willard said.

"There's also the weird psychological aspect of not being able to see their own face or other people's faces and facial expressions," he added, "which really interferes with communication and signals that they [feel are safe]."

To ease their mask fears, buy or make coverings with appealing fabrics, or draw something cool with markers to make them look more fun. Try drawings of your child's favorite superheroes or ninjas wearing masks as they go about helping other people. Show your child your own mask and how, by wearing one, he'll be just like Mom or Dad. See if you can find pictures of your kid's favorite celebrities wearing masks.

Doing so could make your kids feel like the masks are "theirs" and give them a sense of ownership, making them more excited and more likely to wear them, Willard said.

"I think also knowing that they are protecting others can help, and making it fun by talking about it as dressing up like superheroes or something."

And altruism isn't only for kids, but for everyone wearing a mask for the public good.

"It's part of our social contract to look after one another," Vinetz said. "It's social solidarity for everybody in a public place, when told to by public health and political authorities, [to] wear a face covering according to what's recommended."

The rest is here:
All your questions about how to wear a face mask -- answered - Action News Now

Posted in Nano medicine | Comments Off on All your questions about how to wear a face mask — answered – Action News Now

What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? – AJMC.com Managed Markets Network

Posted: April 24, 2020 at 7:46 pm

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs. CAR-T cell therapies also hold promise for patients with hematologic malignant neoplasms that are unresponsive or resistant to standard treatments, researchers said.

The treatment involves harvesting and reengineering an individuals own cells to attack specific malignant cells. CAR-T cells were initially developed using knowledge gleaned from allogeneic stem cell transplantsthat donor mature immune cells can attack healthy cells in the recipient patient.

In an economic evaluation, researchers used a decision-tree model to document patient clinical outcomes and costs, using only hypothetical patients and facilities. Excluding the CAR T-cell acquisition cost, researchers found hospitalization and office visits comprised 65.3% of the costs in inpatient settings and 48.4% of the costs in outpatient settings. Specifically, outpatient administration of CAR T-cell therapy in nonacademic specialty oncology networks was associated with a $32,987 (40.4%) reduction in total costs. Sensitivity analyses were carried out to address assumptions made to build the model.

Before the approval of CAR T-cell therapy, the available treatments for patients with relapsed or refractory LBCL included high-dose chemotherapy, salvage chemotherapy, and autologous hematopoietic stem cell transplantation (auto-HSCT); however, the prognosis after these treatments is often poor, authors said.

Researchers analyzed a predefined period from lymphodepletion to 30 days after the receipt of CAR T-cell infusion, in order to account for potential incidences of adverse events. Data were collected from several sources including theHealthcare Cost and Utilization Project National Inpatient Sample and the Medicare Hospital Outpatient Prospective Payment System. Investigators used secondary literature to inform model inputs.

Total cost of therapy included any costs associated with lymphodepletion, acquisition and infusion of CAR T-cells and management of acute adverse events.

The model also showed:

In this scenario, the model found patients who received CAR T-cell therapy in a nonacademic specialty oncology network setting would save $27,294 compared with the inpatient setting. In addition, in the scenario analysis the decrease in incremental cost reductions was associated with a lower overall incidence of AEs, which reduced the consequences of associated AE management costs, while the monitoring required at baseline was held constant.

The results indicate CAR T-cell therapy with a better safety profile may be more economical and could further leverage the outpatient site of care, researchers said. They concluded, The potential availability of CAR T-cell therapies with lower AE rates that are suitable for outpatient administration may reduce the total costs of care.

One limit to the study highlighted by the authors is the fact that outpatient administration may not be an option for all patients with LBCL.Eligibility can be contingent on the patients health status, support system, or the availability of housing near hospitals.

However, some specialists predict a gradual shift of all CAR T-cell therapies to the outpatient setting. Part of the reason for that [shift] is the way that it's reimbursed as an outpatient therapy is slightly more favorableso, financially it is better to do that, said John Sweetenham, MD, professor in the Department of Internal Medicine at UT Southwestern Medical Center and the Associate Director for Clinical Affairs at UTSWs Harold C. Simmons Comprehensive Cancer Center.

He continued, The problem is that these are very toxic treatments, and that many of the patients are not going to be manageable in the outpatient setting; but I do see that as one of the factors which is influencing a slow transition to outpatient CAR-Ts.

Expanded access to novel therapies in immune-oncology (IO) like CAR T-cell therapy also remains a priority among community level oncologists. Reimbursement, operational, and medical challenges associated with cellular therapy inhibit widespread uptake of the therapy, explained Lee Schwartzberg, MD, FACP, chief medical officer and board member at OneOncology. Only a small number of patients, frankly, have been treated with the first-generation CAR-T cells. So we need to develop new technologies and new operational models to do this, he said in an interview with The American Journal of Managed Care.

Reference

Lyman GH, Nguyen A, Snyder S, et al. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma [published online April 6, 2020]. JAMA Netw Open. doi: 10.1001/jamanetworkopen.2020.2072.

More:
What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network

Posted in Cell Therapy | Comments Off on What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? – AJMC.com Managed Markets Network

Page 1,050«..1020..1,0491,0501,0511,052..1,0601,070..»